Back to Journals » International Journal of Nanomedicine » Volume 7

Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model

Authors Li ZR, Wu XH, Li JG, Yao L, Sun LM, Shi YY, Zhang WX, Lin JX, Liang D, Li YP

Received 14 January 2012

Accepted for publication 20 February 2012

Published 9 May 2012 Volume 2012:7 Pages 2389—2398

DOI https://doi.org/10.2147/IJN.S29945

Review by Single-blind

Peer reviewer comments 3

Zhanrong Li,1,* Xianghua Wu,1,* Jingguo Li,2 Lin Yao,1 Limei Sun,1 Yingying Shi,1 Wenxin Zhang,1 Jianxian Lin,1 Dan Liang,1 Yongping Li1

1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, 2School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou, People's Republic of China

*These authors contributed equally to this work

Background: Celastrol, a Chinese herbal medicine, has shown antitumor activity against various tumor cell lines. However, the effect of celastrol on retinoblastoma has not yet been analyzed. Additionally, the poor water solubility of celastrol restricts further therapeutic applications. The goal of this study was to evaluate the effect of celastrol nanoparticles (CNPs) on retinoblastoma and to investigate the potential mechanisms involved.
Methods: Celastrol-loaded poly(ethylene glycol)-block-poly(ε-caprolactone) nanopolymeric micelles were developed to improve the hydrophilicity of celastrol. The 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulf-ophenyl)-2H tetrazolium monosodium salt (WST-8) assay was used to determine the inhibitory effect of CNPs on SO-Rb 50 cell proliferation in vitro. Immunofluorescence was used to evaluate the apoptotic effect of CNPs on nuclear morphology, and flow cytometry was used to quantify cellular apoptosis. The expression of Bcl-2, Bax, NF-κB p65, and phospo-NF-κB p65 proteins was assessed by Western blotting. A human retinoblastoma xenograft model was used to evaluate the inhibitory effects of CNPs on retinoblastoma in NOD-SCID mice. Hematoxylin and eosin staining was used to assess the apoptotic effects of CNPs on retinoblastoma.
Results: CNPs inhibit the proliferation of SO-Rb 50 cells in a dose- and time-dependent manner with an IC50 of 17.733 µg/mL (celastrol-loading content: 7.36%) after exposure to CNPs for 48 hours. CNPs induce apoptosis in SO-Rb 50 cells in a dose-dependent manner. The expression of Bcl-2, NF-κB p65, and phospo-NF-κB p65 proteins decreased after exposure to CNPs 54.4 µg/mL for 48 hours. Additionally, the Bax/Bcl-2 ratio increased, whereas the expression of Bax itself was not significantly altered. CNPs inhibit the growth of retinoblastoma and induce apoptosis in retinoblastoma cells in mice.
Conclusion: CNPs inhibit the growth of retinoblastoma in mouse xenograft model by inducing apoptosis in SO-Rb 50 cells, which may be related to the increased Bax/Bcl-2 ratio and the inhibition of NF-κB. CNPs may represent a potential alternative treatment for retinoblastoma.

Keywords: apoptosis, SO-Rb 50 cells, poly(ethylene glycol)-block-poly(ε-caprolactone), nanopolymeric micelles, celastrol nanoparticles
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia

Albayarak Y, Akyol ES, Beyazyüz M, Baykal S, Kuloglu M

Neuropsychiatric Disease and Treatment 2015, 11:2825-2831

Published Date: 29 October 2015

Efficacy and safety of nanohybrids comprising silver nanoparticles and silicate clay for controlling Salmonella infection

Chiao SH, Lin SH, Shen CI, Liao JW, Bau IJ, Wei JC, Tseng LP, Hsu SH, Lai PS, Lin SZ, Lin JJ, Su HL

International Journal of Nanomedicine 2012, 7:2421-2432

Published Date: 14 May 2012

Association between calcifying nanoparticles and placental calcification

Guo Y, Zhang D, Lu H, Luo S, Shen X

International Journal of Nanomedicine 2012, 7:1679-1686

Published Date: 27 March 2012

Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer

Tan BJ, Liu Y, Chang KL, Lim BKW, Chiu GNC

International Journal of Nanomedicine 2012, 7:651-661

Published Date: 8 February 2012

Bactericidal activities of woven cotton and nonwoven polypropylene fabrics coated with hydroxyapatite-binding silver/titanium dioxide ceramic nanocomposite "Earth-plus"

Kasuga E, Kawakami Y, Matsumoto T, Hidaka E, Oana K, Ogiwara N, Yamaki D, Sakurada T, Honda  T

International Journal of Nanomedicine 2011, 6:1937-1943

Published Date: 9 September 2011

New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo

Zhou T, Jia X, Li H, Wang J, Zhang H, A Y, Zhang ZZ

International Journal of Nanomedicine 2011, 6:1527-1534

Published Date: 22 July 2011

Poly (ε-caprolactone) nanofibrous ring surrounding a polyvinyl alcohol hydrogel for the development of a biocompatible two-part artificial cornea

Bakhshandeh H, Soleimani M, Shah Hosseini S, Hashemi H, Shabani I, Shafiee A, Behesht Nejad AH, Erfan M, Dinarvand R, Atyabi F

International Journal of Nanomedicine 2011, 6:1509-1515

Published Date: 14 July 2011

Study of pharmacokinetics and tissue distribution of liposomal brucine for dermal administration

Yang B-C, Chu Z-F, Zhu S, Wang L-J, Feng Y-H, Li F-H, Liu C-S, Yuan Y

International Journal of Nanomedicine 2011, 6:1109-1116

Published Date: 26 May 2011